Senseonics Anticipates FY Revenue of $34-38 Million

Senseonics Holdings, a medical technology company, has reported FY revenue guidance of $34-38 million. The company develops and manufactures glucose monitoring products, including Eversense, Eversense XL, and Eversense E3, which use a small sensor inserted under the skin to transmit glucose data to a mobile app. The system can continuously and accurately measure glucose levels for up to six months.

Senseonics Holdings, Inc. (NYSE American: SENS), a leading innovator in long-term implantable continuous glucose monitoring systems, has reported its fiscal year (FY) 2025 revenue guidance. The company expects global net revenue of $34-38 million, a significant milestone in its growth trajectory. This financial outlook underscores Senseonics' commitment to advancing diabetes care through innovative medical technology.

Key to this guidance is the company's strategic shift in the commercialization of its Eversense 365 system. Senseonics has signed a Memorandum of Understanding (MOU) with Ascensia Diabetes Care, effective January 1, 2026, to take over global commercialization and distribution of Eversense 365. This move aims to enhance the system's market penetration and improve patient access to advanced diabetes management solutions. The appointment of Brian Hansen as Chief Commercial Officer and an expanded debt facility of up to $100 million with Hercules Capital are pivotal steps in executing this strategy [1].

Senseonics' financial results for the first two quarters of FY 2025 have shown promising growth. Q1 2025 revenue reached $6.3 million, with a 24% year-over-year increase, driven by partnerships and CMS reimbursements. Q2 2025 revenue climbed to $6.6 million, a 37% year-over-year increase, primarily driven by a 79% increase in U.S. new patient starts. Despite these gains, the company reported a net loss of $14.5 million for Q2 2025, reflecting the high investment in R&D and commercialization efforts [2].

The company's fiscal year 2025 expectations include doubling its global patient base, with gross margins projected between 32.5% and 37.5%. Cash used in operations is expected to be approximately $60 million, reflecting the company's aggressive approach to market expansion and product development [3].

Senseonics' strategic partnerships and product integrations are also driving growth. The integration of Sequel Med Tech's twiist™ AID system with Eversense 365, expected to launch in Q3 2025, offers enhanced diabetes management tools. This collaboration represents a significant advancement in automated insulin delivery systems, combining Senseonics' Eversense 365 CGM with Sequel's advanced AID technology [4].

Investors can stay informed about Senseonics' progress through its upcoming events. The company has scheduled earnings releases and conference calls for Q1 and Q2 2025, providing insights into its financial performance. Additionally, an analyst event at ADA 2025 will showcase the Eversense 365 system and discuss future innovations [5].

In summary, Senseonics Holdings' FY 2025 revenue guidance reflects a robust growth trajectory driven by strategic partnerships, product innovations, and aggressive commercialization efforts. The company's focus on advancing diabetes care through innovative medical technology positions it as a key player in the medical device industry.

References:
[1] https://www.stocktitan.net/news/SENS/
[2] https://www.stocktitan.net/news/SENS/
[3] https://www.stocktitan.net/news/SENS/
[4] https://www.stocktitan.net/news/SENS/
[5] https://www.stocktitan.net/news/SENS/